04.16.12
Salt Lake City, UT-based Schiff Nutrition International, Inc., has acquired Airborne, Inc., for $150 million in cash, according to a press release issued by Schiff.
“Schiff is focused on building premium brands and leading innovation,” stated Tarang Amin, president and chief executive officer. “We are excited about the Airborne acquisition, which fits well with our strategy and establishes Schiff as a leader in the immune support segment. Airborne is a strong brand and will make an excellent addition to Schiff’s portfolio, and we plan to leverage our science, innovation, marketing and sales capabilities to further its growth.”
Marti Morfitt, Airborne, Inc.’s chief executive officer, stated: “I am very proud of the work the Airborne team has done over the past three years to re-establish the growth of the brand and to develop a strong pipeline of new products and marketing programs designed to support the future growth of the business. We are happy to see our business move to the team at Schiff – they bring great talent and resources to the business and share our passion for building a leading immune support brand.”
“Schiff intends to couple Airborne’s leading brand and product portfolio with our strong capabilities in science and innovation,” continued Amin. “For example, there has been promising scientific research into the potential relationship between BC30, the proprietary probiotics technology we acquired rights to last year, and supporting the immune system. We are currently conducting a study with Dr. Glenn R. Gibson at The University of Reading in the UK on the effects of BC30 on the immune function of healthy elderly persons. This is but one of the many potential opportunities to bring science and innovation to Airborne.”
“Schiff is focused on building premium brands and leading innovation,” stated Tarang Amin, president and chief executive officer. “We are excited about the Airborne acquisition, which fits well with our strategy and establishes Schiff as a leader in the immune support segment. Airborne is a strong brand and will make an excellent addition to Schiff’s portfolio, and we plan to leverage our science, innovation, marketing and sales capabilities to further its growth.”
Marti Morfitt, Airborne, Inc.’s chief executive officer, stated: “I am very proud of the work the Airborne team has done over the past three years to re-establish the growth of the brand and to develop a strong pipeline of new products and marketing programs designed to support the future growth of the business. We are happy to see our business move to the team at Schiff – they bring great talent and resources to the business and share our passion for building a leading immune support brand.”
“Schiff intends to couple Airborne’s leading brand and product portfolio with our strong capabilities in science and innovation,” continued Amin. “For example, there has been promising scientific research into the potential relationship between BC30, the proprietary probiotics technology we acquired rights to last year, and supporting the immune system. We are currently conducting a study with Dr. Glenn R. Gibson at The University of Reading in the UK on the effects of BC30 on the immune function of healthy elderly persons. This is but one of the many potential opportunities to bring science and innovation to Airborne.”